Enroller Experience and Parental Familiarity of Disease Influence Participation in a Pediatric Trial

Jeff E Schunk1, Kammy K Jacobsen1, Dilon Stephens1

  • 1University of Utah School of Medicine, Department of Pediatrics, Salt Lake City, Utah.

Insights

Parental consent for pediatric clinical trials is crucial. Familiarity with diabetic ketoacidosis (DKA) and enroller experience significantly increased parental permission rates in a DKA therapies study.

Area of Science:

  • Pediatric clinical research
  • Medical ethics in research
  • Diabetology

Background:

  • Parental consent is essential for pediatric clinical research, particularly in interventional studies.
  • Understanding factors influencing consent is key to successful trial recruitment.
  • This study focused on enrollment in a trial for therapies for diabetic ketoacidosis (DKA) in children.

Purpose of the Study:

  • To investigate demographic, clinical, and environmental factors affecting parental permission for pediatric DKA research.
  • To identify predictors of consent in interventional pediatric trials.
  • To enhance recruitment strategies for pediatric clinical research.

Main Methods:

  • Analysis of data from 250 patient/parent dyads approached for the PECARN FLUID trial.
  • Utilized bivariable and multivariable analyses to assess factors influencing enrollment.
  • Controlled for enroller characteristics in the statistical models.

Main Results:

  • 71% of parents consented to their child's participation.
  • Higher consent rates were observed for children with prior DKA episodes compared to new-onset diabetes.
  • Enrollment was significantly more likely with experienced enrollers (OR 2.46).

Conclusions:

  • Prior DKA history and enroller experience are significant positive predictors of parental consent.
  • Factors like patient age, gender, insurance, and DKA severity did not influence participation likelihood.
  • Findings can inform strategies to improve consent rates in pediatric DKA trials.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
31
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
37
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
25
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
35